Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

Early outcomes and the virological effect of delayed treatment switching to second-line therapy in an antiretroviral roll-out programme in South Africa.

Levison JH, Orrell C, Losina E, Lu Z, Freedberg KA, Wood R.

Antivir Ther. 2011;16(6):853-61. doi: 10.3851/IMP1819.

2.

Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets.

Decloedt EH, McIlleron H, Smith P, Merry C, Orrell C, Maartens G.

Antimicrob Agents Chemother. 2011 Jul;55(7):3195-200. doi: 10.1128/AAC.01598-10.

3.
4.

Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis.

Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, Kozal MJ, Hullsiek KH, Balduin M, Jakobsen MR, Geretti AM, Thiebaut R, Ostergaard L, Masquelier B, Johnson JA, Miller MD, Kuritzkes DR.

JAMA. 2011 Apr 6;305(13):1327-35. doi: 10.1001/jama.2011.375. Review.

5.

Global trends in molecular epidemiology of HIV-1 during 2000-2007.

Hemelaar J, Gouws E, Ghys PD, Osmanov S; WHO-UNAIDS Network for HIV Isolation and Characterisation..

AIDS. 2011 Mar 13;25(5):679-89. doi: 10.1097/QAD.0b013e328342ff93.

6.

Detection of low-level K65R variants in nucleoside reverse transcriptase inhibitor-naive chronic and acute HIV-1 subtype C infections.

Li JF, Lipscomb JT, Wei X, Martinson NA, Morris L, Heneine W, Johnson JA.

J Infect Dis. 2011 Mar 15;203(6):798-802. doi: 10.1093/infdis/jiq126.

7.

Update of the drug resistance mutations in HIV-1: December 2010.

Johnson VA, Brun-Vézinet F, Clotet B, Günthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD.

Top HIV Med. 2010 Dec;18(5):156-63. Review.

8.

Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Côte d'Ivoire.

Pasquet A, Messou E, Gabillard D, Minga A, Depoulosky A, Deuffic-Burban S, Losina E, Freedberg KA, Danel C, Anglaret X, Yazdanpanah Y.

PLoS One. 2010 Oct 15;5(10):e13414. doi: 10.1371/journal.pone.0013414.

9.

Why are antiretroviral treatment patients lost to follow-up? A qualitative study from South Africa.

Miller CM, Ketlhapile M, Rybasack-Smith H, Rosen S.

Trop Med Int Health. 2010 Jun;15 Suppl 1:48-54. doi: 10.1111/j.1365-3156.2010.02514.x.

10.

Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa.

El-Khatib Z, Ekstrom AM, Ledwaba J, Mohapi L, Laher F, Karstaedt A, Charalambous S, Petzold M, Katzenstein D, Morris L.

AIDS. 2010 Jul 17;24(11):1679-87. doi: 10.1097/QAD.0b013e32833a097b.

11.

Outcomes after virologic failure of first-line ART in South Africa.

Murphy RA, Sunpath H, Lu Z, Chelin N, Losina E, Gordon M, Ross D, Ewusi AD, Matthews LT, Kuritzkes DR, Marconi VC; South Africa Resistance Cohort Study Team..

AIDS. 2010 Apr 24;24(7):1007-12. doi: 10.1097/QAD.0b013e3283333639.

12.

Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline.

Hosseinipour MC, Kumwenda JJ, Weigel R, Brown LB, Mzinganjira D, Mhango B, Eron JJ, Phiri S, van Oosterhout JJ.

HIV Med. 2010 Sep;11(8):510-8. doi: 10.1111/j.1468-1293.2010.00825.x.

13.

The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa.

Long L, Fox M, Sanne I, Rosen S.

AIDS. 2010 Mar 27;24(6):915-9. doi: 10.1097/QAD.0b013e3283360976.

PMID:
20042849
14.

Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.

Ross LL, Rouse E, Gerondelis P, DeJesus E, Cohen C, Horton J, Ha B, Lanier ER, Elion R; COL40263 study..

J Antimicrob Chemother. 2010 Feb;65(2):307-15. doi: 10.1093/jac/dkp419.

15.

Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1.

Wallis CL, Papathanasopoulos MA, Lakhi S, Karita E, Kamali A, Kaleebu P, Sanders E, Anzala O, Bekker LG, Stevens G, de Wit TF, Stevens W.

J Virol Methods. 2010 Feb;163(2):505-8. doi: 10.1016/j.jviromet.2009.11.011.

16.

High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa.

Fox MP, Ive P, Long L, Maskew M, Sanne I.

J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):500-6. doi: 10.1097/QAI.0b013e3181bcdac1.

PMID:
19838128
17.

Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach.

Geng EH, Bangsberg DR, Musinguzi N, Emenyonu N, Bwana MB, Yiannoutsos CT, Glidden DV, Deeks SG, Martin JN.

J Acquir Immune Defic Syndr. 2010 Mar;53(3):405-11. doi: 10.1097/QAI.0b013e3181b843f0.

18.
19.

Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies.

Nash D, Katyal M, Brinkhof MW, Keiser O, May M, Hughes R, Dabis F, Wood R, Sprinz E, Schechter M, Egger M; ART-LINC Collaboration of IeDEA..

AIDS. 2008 Nov 12;22(17):2291-302. doi: 10.1097/QAD.0b013e3283121ca9.

20.
Items per page

Supplemental Content

Support Center